Infliximab May Lower Glucocorticoid Requirements, Lead to Remission in Takayasu Arteritis
Treatment of active Takayasu arteritis with infliximab may result in remission or in a diminished requirement for glucocorticoids.
Arteritis
Takayasu Arteritis: Efficacy and Safety of Tocilizumab vs Placebo
Tocilizumab therapy improves time to relapse in Takayasu arteritis with a favorable safety and tolerability profile.
FDA Approves First Drug to Specifically Treat Giant Cell Arteritis
Actemra (tocilizumab) has been FDA-approved for its use in giant cell arteritis treatment.
Childhood-Onset Takayasu Arteritis Too Often Overlooked
Takayasu arteritis (TA) can manifest in childhood and the symptoms may be overlooked, leading to delay in diagnosis and poor outcomes. A study that included 40 children with TA provides insights on the diagnosis and treatment of this rare and potentially life-threatening condition.
Next post in General Rheumatology
